BioPharma Resources

Drug Trial Radar · NCT06905210

Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris

Phase III Superiority, Randomized, Double-blind, Placebo-controlled, Adaptive, Multicenter Study to Compare the Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-dose Estrogen for the Treatment of Moderate Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 531 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

531

Planned (sponsor's estimate)

Start

Aug 24, 2026

Primary completion

Feb 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Eurofarma Laboratorios S.A.Industry
Sponsor type
Industry
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 14 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study evaluates the efficacy and safety of a new concentration of the fixed-dose combination EF190 in women with moderate acne vulgaris over six 28-day treatment cycles. Eligible participants will be randomized (2:1) to receive either the experimental drug or placebo alongside standard skincare. The study includes five in-person visits (screening, randomization, and three follow-ups) and three phone contacts (cycles 2, 4, and 5) to monitor adherence, adverse events, and contraceptive use. A subgroup will undergo additional exploratory assessments, including acne questionnaires, ovarian activity tests, photographic documentation, and specialized lab/ultrasound exams.

Conditions

  • Acne Vulgaris
  • Acne Vulgaris on the Face

Interventions

  • Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)Drug

    Cyproterone acetate 2 mg and ethinyl estradiol 0.02 mg film-coated tablets administered in a 24+4 regimen. Each treatment pack contains one 28-tablet calendar blister composed of 24 active tablets and 4 inactive tablets. Participants will receive treatment for 6 consecutive 28-day cycles during the double-blind treatment period.

  • PlaceboDrug

    Placebo film-coated tablets administered in a 24+4 regimen. Each treatment pack contains one 28-tablet calendar blister composed of 24 placebo tablets and 4 inactive placebo tablets. Participants will receive treatment for 6 consecutive 28-day cycles during the double-blind treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute reduction from baseline in the number of inflammatory acne lesions assessed at Cycle 6.Time frame: 24 weeks
  2. Absolute reduction from baseline in the total number of acne lesions assessed at Cycle 6.Time frame: 24 weeks
  3. Change from Baseline of participants with scores 0 or 1 in the Static Investigator Global Assessment (ISGA) at cycle 6.Time frame: 24 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Clinica Ibis Salvador

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Instituto de Gestão Estratégica de Saúde do Distrito Federal-IGESDF

    Brasília, Federal District, Brazil · Recruiting

  • ICF Ciências Farmacêutica - Unidade Clínica

    Goiânia, Goiás, Brazil · Recruiting

  • Centro de Pesquisa Clínica - Hospital Ruy Azeredo

    Goiânia, Goiás, Brazil · Recruiting

  • Norte Pesquisa Clínica

    Belém, Pará, Brazil · Recruiting

  • Genthe Pesquisa Clínica

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Artha Pesquisas Clínicas

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Liga Norte Riograndense Contra o Câncer

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Hospital de Clínicas de Passo Fundo

    Passo Fundo, Rio Grande do Sul, Brazil · Recruiting

  • Centro de Pesquisa Clínica Mãe de Deus/AESC

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital Universitário São Francisco na Providência de Deus - HUSF

    Bragança Paulista, São Paulo, Brazil · Recruiting

  • CLINICA GERAL INVESTIGA LTDA (Allergisa)

    Campinas, São Paulo, Brazil · Recruiting

  • Synvia

    Campinas, São Paulo, Brazil · Recruiting

  • Eurofarma Laboratórios S.A

    Itapevi, São Paulo, Brazil · Recruiting

  • CIPES

    São José dos Campos, São Paulo, Brazil · Recruiting

  • Synvia

    São Paulo, São Paulo, Brazil · Recruiting

  • Kosmoscience

    Valinhos, São Paulo, Brazil · Recruiting

  • Azidus

    Valinhos, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.